The meaning of p16ink4aexpression in tumors: Functional significance, clinical associations and future developments

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

Ang, K. K., Harris, J., Wheeler, R. H., Weber, R. S., Rosenthal, D. I., Nguyen‐Tan, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C. S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,573 · see citing works

CDK inhibitors: positive and negative regulators of G1-phase progression

Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · see citing works

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · see citing works

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · see citing works

The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product

Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017 · see citing works

Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial

Fakhry, C., Westra, W. H., Li, S., Cmelak, A. J., Ridge, J. A., Pinto, H. A., Forastiere, A. A., & Gillison, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn011 · Cited by 2,777 · see citing works

A cell cycle regulator potentially involved in genesis of many tumor types

Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1× · see citing works

BRAFE600-associated senescence-like cell cycle arrest of human naevi

Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · see citing works

Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization

Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · see citing works

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · see citing works

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742 · see citing works

Senescence in premalignant tumours

Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482 · see citing works

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264 · see citing works

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · see citing works

Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.

Münger, K., Werness, B. A., Dyson, N. J., Phelps, W. C., Harlow, E. E., & Howley, P. M. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08594.x · Cited by 1,204 · see citing works

A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann, E., Plaen, E. D., Hankeln, T., Büschenfelde, K. M. Z., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,153 · see citing works

Cellular mechanisms of tumour suppression by the retinoblastoma gene

Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974 · see citing works

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899 · see citing works

Identification and properties of an atypical catalytic subunit (p34PSK-J3/Cdk4) for mammalian D type G1 cyclins

Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897 · see citing works

Progression model for pancreatic cancer.

Hruban, R. H., Goggins, M., Parsons, J., & Kern, S. E. (2000) · PubMed · Cited by 872 · see citing works

Role of the p16 tumor suppressor gene in cancer.

Liggett, W. H., & Sidransky, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1197 · Cited by 746 · see citing works

Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

Rischin, D., Young, R. J., Fisher, R., Fox, S. B., Le, Q., Peters, L. J., Solomon, B., Choi, J., O’Sullivan, B., Kenny, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2904 · Cited by 735 · see citing works

Matrix metalloproteinases in tumour invasion and metastasis

Curran, S., & Murray, G. I. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199911)189:3 · Cited by 654 · see citing works

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

Dhomen, N. S., Reis-Filho, J. S., Dias, S. D. R., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C. A., & Marais, R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.022 · Cited by 590 · see citing works

p16 ^INK4A is a robust <i>in vivo</i> biomarker of cellular aging in human skin

Ressler, S., Bartkova, J., Niederegger, H., Bartek, J., Scharffetter‐Kochanek, K., Jansen‐Dürr, P., & Wlaschek, M. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00231.x · Cited by 557 · see citing works

Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a

Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524 · see citing works

Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation.Preprint

Xiong, Y., Zhang, H., & Beach, D. (1993) · Genes & Development · doi:10.1101/gad.7.8.1572 · Cited by 507 · see citing works

Assembly of cyclin D-dependent kinase and titration of p27 ^Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)

Cheng, M., Sexl, V., Sherr, C. J., & Roussel, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1091 · Cited by 496 · see citing works

Growth suppression by p16ink4 requires functional retinoblastoma protein

Medema, R. H., Herrera, R. E., Lam, F., & Weinberg, R. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6289 · Cited by 433 · see citing works

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393 · see citing works

Retinoblastoma protein partners

(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)82001-7 · Cited by 349 · see citing works

Tailoring to RB: tumour suppressor status and therapeutic response

Knudsen, E. S., & Knudsen, K. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2401 · Cited by 345 · see citing works

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression

Sharma, A. M., Yeow, W.-S., Ertel, A., Coleman, I. M., Clegg, N. J., Thangavel, C., Morrissey, C. M., Zhang, X., Comstock, C. E. S., Witkiewicz, A. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44239 · Cited by 327 · see citing works

Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts

Michaud, K., Solomon, D. A., Oermann, E. K., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 321 · see citing works

Absence of p16(INK4) protein is restricted to the subset of lung cancer lines that retains wildtype RB

Otterson, G. A. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)98734-r · Cited by 313 · see citing works

Dual Mechanisms for the Inhibition of E2F Binding to RB by Cyclin-Dependent Kinase-Mediated RB Phosphorylation

Knudsen, E. S., & Wang, J. Y. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5771 · Cited by 286 · see citing works

Mutations associated with familial melanoma impair p16INK4 function

Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280 · see citing works

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas

Herschkowitz, J. I., He, X., Fan, C., & Perou, C. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2142 · Cited by 255 · see citing works

Suppressing Cancer: The Importance of Being Senescent

Campisi, J. (2005) · Science · doi:10.1126/science.1116801 · Cited by 250 · see citing works

Management of Small Cell Lung Cancer

Simon, G. R., & Turrisi, A. T. (2007) · CHEST Journal · doi:10.1378/chest.07-1385 · Cited by 225 · see citing works

Abrogated Response to Cellular Stress Identifies DCIS Associated with Subsequent Tumor Events and Defines Basal-like Breast Tumors

Gauthier, M. L., Berman, H. K., Miller, C., Kozakeiwicz, K., Chew, K., Moore, D., Rabban, J., Chen, Y. Y., Kerlikowske, K., & Tlsty, T. D. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.017 · Cited by 214 · see citing works

The Relationship Between Human Papillomavirus Status and Other Molecular Prognostic Markers in Head and Neck Squamous Cell Carcinomas

Kong, C. S., Narasimhan, B., Cao, H., Kwok, S., Erickson, J. P., Koong, A. C., Pourmand, N., & Le, Q. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.02.015 · Cited by 213 · see citing works

Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progressionPreprint

Knudsen, E. S., Buckmaster, C., Chen, T.-T., Feramisco, J. R., & Wang, J. Y. J. (1998) · Genes & Development · doi:10.1101/gad.12.15.2278 · Cited by 210 · see citing works

Targeting the RB-pathway in Cancer Therapy

Knudsen, E. S., & Wang, J. Y. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0787 · Cited by 204 · see citing works

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

Bosco, E. E., Wang, Y., Xu, H., Zilfou, J. T., Knudsen, K. E., Aronow, B. J., Lowe, S. W., & Knudsen, E. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28803 · Cited by 192 · see citing works

Role of the CDKN2A Locus in Patients With Multiple Primary Melanomas

Puig, S., Malvehy, J., Bádenas, C., Ruiz, A., Jiménez, D., Cuéllar, F., Azón, A., González, U., CASTEL, T., Campoy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.034 · Cited by 147 · see citing works

E2F-associated chromatin modifiers and cell cycle control

Blais, A., & Dynlacht, B. D. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.10.003 · Cited by 146 · see citing works

Cell cycle control and cancer.

Sherr, C. J. (2002) · PubMed · Cited by 138 · see citing works

Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells

Rivadeneira, D. B., Mayhew, C. N., Thangavel, C., Sotillo, E., Reed, C. A., Graña, X., & Knudsen, E. S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.007 · Cited by 127 · see citing works

Most Basal-like Breast Carcinomas Demonstrate the Same Rb−/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically

Subhawong, A. P., Subhawong, T. K., Nassar, H., Kouprina, N., Begum, S., VANG, R. S., Westra, W. H., & Argani, P. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31817f9790 · Cited by 111 · see citing works

Retinoblastoma Tumor Suppressor: Where Cancer Meets the Cell Cycle

Knudsen, E. S., & Knudsen, K. E. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100713 · Cited by 105 · see citing works

Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.

Ct, L., Capodieci, P., Osman, I., Fazzari, M. J., Ferrara, J., Scher, H. I., & Cordon‐Cardo, C. (1999) · PubMed · Cited by 105 · see citing works

Aberrations of p16Ink4 and retinoblastoma tumour‐suppressor genes occur in distinct sub‐sets of human cancer cell lines

Aagaard, L., Lukas, J., Bártková, J., Kjerulff, A. A., Strauss, M., & Bártek, J. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610120 · Cited by 102 · see citing works

Differential Inactivation of CDKN2 and Rb Protein in Non--Small-Cell and Small-Cell Lung Cancer Cell Lines

Kelley, M. J., Nakagawa, K., Steinberg, S., Mulshine, J. L., Kamb, A., & Johnson, B. E. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.756 · Cited by 80 · see citing works

Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients.

Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., & Sutherland, R. L. (2001) · PubMed · Cited by 80 · see citing works

Human Papillomavirus and Head and Neck Cancer

Mendenhall, W. M., & Logan, H. L. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31818b8fee · Cited by 67 · see citing works

Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis

Tort, F., Bártková, J., Sehested, M., Orntoft, T. F., Lukas, J., & Bártek, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2178 · Cited by 66 · see citing works

Prognostic Value of p16 in Locally Advanced Prostate Cancer: A Study Based on Radiation Therapy Oncology Group Protocol 9202

Chakravarti, A., DeSilvio, M., Zhang, M., Grignon, D. J., Rosenthal, S. A., Asbell, S. O., Hanks, G. E., Sandler, H. M., Khor, L.-Y., Pollack, A. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.4152 · Cited by 52 · see citing works

Loss of Rb overrides the requirement for ERK activity for cell proliferation

D’Abaco, G. M., Hooper, S., Paterson, H., & Marshall, C. J. (2002) · Journal of Cell Science · doi:10.1242/jcs.00161 · Cited by 34 · see citing works

Regulation of CYL /Cyclin D Genes by Colony‐Stimulating Factor 1

Sherr, C. J., Matsushime, H., & Roussel, M. F. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514320.ch13 · Cited by 24 · see citing works

S-phase lengthening induced by p16INK4aoverexpression in malignant cells with wild-type pRb and p53

Chien, W. W., Domenech, C., Catallo, R., Salles, G., & Ffrench, M. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12600 · Cited by 15 · see citing works

Paradoxical down-regulation of p16 mRNA with advancing age in Acute Myeloid Leukemia

de Jonge, H. J. M., Woolthuis, C. M., de Bont, E. S. J. M., & Huls, G. A. (2009) · Aging · doi:10.18632/aging.100096 · Cited by 14 · see citing works

Cellular senescence in ageing: from mechanisms to therapeutic opportunities

Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277 · see citing works

The history and future of targeting cyclin-dependent kinases in cancer therapy

Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767 · see citing works

Forging a signature of in vivo senescence

Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104 · see citing works

Ageing, Cellular Senescence and Neurodegenerative Disease

Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448 · see citing works

A multidimensional systems biology analysis of cellular senescence in aging and disease

Avelar, R. A., Ortega, J. G., Tacutu, R., Tyler, E. J., Bennett, D., Binetti, P., Budovsky, A., Chatsirisupachai, K., Johnson, E., Murray, A., et al. (2020) · Genome Biology · doi:10.1186/s13059-020-01990-9 · Cited by 399 · see citing works

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Pandey, K., An, H. J., Kim, S., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2018) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 366 · see citing works

Senescence from G2 arrest, revisited

Gire, V., & Dulić, V. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1000134 · Cited by 300 · see citing works

The Molecular Balancing Act of p16INK4a in Cancer and Aging

LaPak, K. M., & Burd, C. E. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 294 · see citing works

The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies

Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285 · see citing works

Signaling through cyclin D-dependent kinases

Choi, Y., & Anders, L. (2013) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 279 · see citing works

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226 · see citing works

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

Franco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207 · see citing works

CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation

Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204 · see citing works

Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities

Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.094 · Cited by 199 · see citing works

Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy

Knudsen, E. S., Pruitt, S. C., Hershberger, P. A., Witkiewicz, A. K., & Goodrich, D. W. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.03.005 · Cited by 185 · see citing works

Techniques to induce and quantify cellular senescence

Noren Hooten, N., & Evans, M. K. (2017) · Journal of Visualized Experiments · doi:10.3791/55533 · Cited by 178 · see citing works

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168 · see citing works

Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer

Portman, N., Alexandrou, S., Carson, E., Wang, S., Lim, E., & Caldon, C. E. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0317 · Cited by 161 · see citing works

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J., White, H. S., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 160 · see citing works

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

George, M. A., Qureshi, S., Omene, C. O., Toppmeyer, D., & Ganesan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693104 · Cited by 156 · see citing works

Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs

Yuan, K., Wang, X., Dong, H., Min, W., Hao, H., & Yang, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.001 · Cited by 147 · see citing works

The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer

Peurala, E., Koivunen, P., Haapasaari, K., Bloigu, R., & Jukkola‐Vuorinen, A. (2013) · Breast Cancer Research · doi:10.1186/bcr3376 · Cited by 142 · see citing works

Endoplasmic Reticulum (ER) Stress and Its Role in Pancreatic β-Cell Dysfunction and Senescence in Type 2 Diabetes

Lee, J., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094843 · Cited by 147 · see citing works

The role of epigenetics in the biology of multiple myeloma

Dimopoulos, K., Gimsing, P., & Grønbæk, K. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.29 · Cited by 133 · see citing works

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities

Knudsen, E. S., Kumarasamy, V. M., Nambiar, R., Pearson, J. D., Vail, P. J., Rosenheck, H. R., Wang, J., Eng, K., Bremner, R., Schramek, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110448 · Cited by 128 · see citing works

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 126 · see citing works

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

Montaudon, É., Nikitorowicz-Buniak, J., Sourd, L., Morisset, L., Botty, R. E., Huguet, L., Dahmani, A., Painsec, P., Némati, F., Vacher, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17697-1 · Cited by 122 · see citing works

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models

Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.24 · Cited by 121 · see citing works

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion

Leontieva, O. V., & Blagosklonny, M. V. (2013) · Cell Cycle · doi:10.4161/cc.26130 · Cited by 119 · see citing works

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments

Presti, D., & Quaquarini, E. (2019) · Cancers · doi:10.3390/cancers11091242 · Cited by 116 · see citing works

Cardamonin: A new player to fight cancer via multiple cancer signaling pathways

Nawaz, J., Rasul, A., Shah, M. A., Hussain, G., Riaz, A., Sarfraz, I., Zafar, S., Adnan, M., Khan, A. H., & Selamoğlu, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117591 · Cited by 114 · see citing works

Pan-cancer molecular analysis of the RB tumor suppressor pathway

Knudsen, E. S., Nambiar, R., Rosario, S. R., Smiraglia, D. J., Goodrich, D. W., & Witkiewicz, A. K. (2020) · Communications Biology · doi:10.1038/s42003-020-0873-9 · Cited by 118 · see citing works

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

Knudsen, E. S., O'Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 108 · see citing works

Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth

Guan, X., LaPak, K. M., Hennessey, R. C., Yu, C. Y., Shakya, R., Zhang, J., & Burd, C. E. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0319 · Cited by 104 · see citing works

An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers

Chohan, T. A., Qayyum, A., Rehman, K., Tariq, M., & Akash, M. S. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.116 · Cited by 102 · see citing works

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Witkiewicz, A. K., Chung, S., Brough, R., Vail, P. J., Franco, J., Lord, C. J., & Knudsen, E. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.022 · Cited by 99 · see citing works

Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies

Xu, X., Pan, X., Wang, T., Wang, J., Yang, B., He, Q., & Ding, L. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0416-4 · Cited by 99 · see citing works

Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00124 · Cited by 94 · see citing works

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets

Enkner, F., Pichlhöfer, B., Zaharie, A., Krunic, M., Holper, T. M., Janik, S., Moser, B., Schlangen, K., Neudert, B., Walter, K., et al. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0144-8 · Cited by 96 · see citing works

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

Rambau, P., Vierkant, R. A., Intermaggio, M. P., Kelemen, L. E., Goodman, M. T., Herpel, E., Pharoah, P. D. P., Kommoss, S., Jimenez‐Liñan, M., Karlan, B. Y., et al. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.109 · Cited by 94 · see citing works

Correction: CDK4/ 6 inhibition provides a potent adjunct to Her2- targeted therapies in preclinical breast cancer models

Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.211 · Cited by 93 · see citing works

p16INK4A Represses the paracrine tumor-promoting effects of breast stromal fibroblasts

Al‐Ansari, M. M., Hendrayani, S., Shehata, A. I., & Aboussekhra, A. (2012) · Oncogene · doi:10.1038/onc.2012.270 · Cited by 88 · see citing works

Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition

Kumarasamy, V. M., Vail, P. J., Nambiar, R., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2275 · Cited by 88 · see citing works

Suppression of p16 alleviates the senescence-associated secretory phenotype

(2021) · doi:10.18632/aging.202640 · Cited by 84 · see citing works

Aminoacyl-tRNA synthetases and amino acid signaling

Yu, Y. C., Han, J. M., & Kim, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118889 · Cited by 82 · see citing works

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art

Randall, J. M., Millard, F. E., & Kurzrock, R. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9533-1 · Cited by 81 · see citing works

Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma

van Oosterwijk, J. G., Anninga, J., Gelderblom, H. A. J., Cleton-Jansen, A., & Bovée, J. V. M. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.07.012 · Cited by 81 · see citing works

α-Fucosidase as a novel convenient biomarker for cellular senescence

Hildebrand, D. G., Lehle, S., Borst, A., Haferkamp, S., Eßmann, F., & Schulze‐Osthoff, K. (2013) · Cell Cycle · doi:10.4161/cc.24944 · Cited by 79 · see citing works

Biomarkers for cervical cancer screening: the role of p16INK4ato highlight transforming HPV infections

Doeberitz, M. V. K., Reuschenbach, M., Schmidt, D., & Bergeron, C. (2012) · Expert Review of Proteomics · doi:10.1586/epr.12.13 · Cited by 77 · see citing works

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 74 · see citing works

Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts

Xie, Z., Hou, S., Yang, X., Duan, Y., Han, J., Wang, Q., & Liao, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02190 · Cited by 73 · see citing works

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

Li, Z., Zou, W., Zhang, J., Zhang, Y., Xu, Q., Li, S., & Chen, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580251 · Cited by 73 · see citing works

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review

Garutti, M., Targato, G., Buriolla, S., Palmero, L., Minisini, A. M., & Puglisi, F. (2021) · Cells · doi:10.3390/cells10061334 · Cited by 72 · see citing works

The Effects of Cigarette Smoking Extracts on Cell Cycle and Tumor Spread: Novel Evidence

Pezzuto, A., Citarella, F., Croghan, I. T., & Tonini, G. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0017 · Cited by 71 · see citing works

Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review

Mesgari, H., Esmaelian, S., Nasiri, K., Ghasemzadeh, S., Doroudgar, P., & Payandeh, Z. (2023) · Cancers · doi:10.3390/cancers15235600 · Cited by 81 · see citing works

RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer

Witkiewicz, A. K., Ertel, A., McFalls, J. M., Valsecchi, M. E., Schwartz, G. F., & Knudsen, E. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0903 · Cited by 70 · see citing works

Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: A review

Pezzuto, A., D’Ascanio, M., Rícci, A., Pagliuca, A., & Carico, E. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13651 · Cited by 69 · see citing works

Functional and pathologic association of aminoacyl-tRNA synthetases with cancer

Sung, Y., Yoon, I., Han, J. M., & Kim, S. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00765-5 · Cited by 68 · see citing works

Practical issues in the application of p16 immunohistochemistry in diagnostic pathology

Mahajan, A. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.12.021 · Cited by 67 · see citing works

Tumour selective targeting of cell cycle kinases for cancer treatment

Aarts, M., Linardopoulos, S., & Turner, N. C. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.012 · Cited by 67 · see citing works

Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer

Knudsen, E. S., Kumarasamy, V. M., Ruiz, A., Sivinski, J., Chung, S., Grant, A. D., Vail, P. J., Chauhan, S. S., Jie, T., Riall, T. S., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0650-0 · Cited by 64 · see citing works

Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer

Papadimitriou, M., Pazaiti, A., Iliakopoulos, K., Markouli, M., Michalaki, V., & PAPADIMITRIOU, C. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119346 · Cited by 65 · see citing works

Hsa_circ_0014717 is downregulated in colorectal cancer and inhibits tumor growth by promoting p16 expression

Wang, F., Wang, J., Cao, X., Xu, L., & Chen, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.015 · Cited by 65 · see citing works

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Hu, Y., Gao, J., Wang, M., & Li, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310649 · Cited by 64 · see citing works

Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition

Rahman, M., Olson, I., Mansour, M. A., Carlstrom, L. P., Sutiwisesak, R., Saber, R., Rajani, K. R., Warrington, A. E., Howard, A., Schroeder, M. A., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0029 · Cited by 63 · see citing works

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers

Marangoni, E., Laurent, C., Coussy, F., Botty, R. E., Château‐Joubert, S., Servely, J., de Plater, L., Assayag, F., Dahmani, A., Montaudon, É., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3490 · Cited by 63 · see citing works

Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma

Novak, M., Lester, J., Karst, A. M., Parkash, V., Hirsch, M. S., Crum, C. P., Karlan, B. Y., & Drapkin, R. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.07.100 · Cited by 60 · see citing works

Cancer takes many paths through G1/S

Knudsen, E. S., Witkiewicz, A. K., & Rubin, S. M. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.10.007 · Cited by 57 · see citing works

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

Witkiewicz, A. K., Borja, N. A., Franco, J., Brody, J. R., Yeo, C. J., Mansour, J., Choti, M. A., McCue, P., & Knudsen, E. S. (2015) · Oncotarget · doi:10.18632/oncotarget.3819 · Cited by 56 · see citing works

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective

Zhou, F. H., Downton, T. D., Freelander, A., Hurwitz, J., Caldon, C. E., & Lim, E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1148792 · Cited by 55 · see citing works

BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma

Lee, H. E., Molina, J. R., Sukov, W. R., Roden, A. C., & Yi, E. S. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.05.001 · Cited by 55 · see citing works

Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma

Milea, A. L., George, S. H. L., Matevski, D., Jiang, H., Madunic, M., Berman, H. K., Gauthier, M. L., Gallie, B. L., & Shaw, P. A. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.218 · Cited by 54 · see citing works

Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy

Witkiewicz, A. K., Kumarasamy, V. M., Sanidas, I., & Knudsen, E. S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.006 · Cited by 51 · see citing works

Expression of p16 in squamous cell carcinoma of the mobile tongue is independent of HPV infection despite presence of the HPV-receptor syndecan-1

Sgaramella, N., Coates, P. J., Strindlund, K., Loljung, L., Colella, G., Laurell, G. F. E., Rossiello, R., Muzio, L. L., Loizou, C., Tartaro, G., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.207 · Cited by 50 · see citing works

Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture

Mi, H., Bivalacqua, T. J., Kates, M. R., Seiler, R., Black, P. C., Popel, A. S., & Baras, A. S. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100382 · Cited by 47 · see citing works

Detecting DNA Methylation of the BCL2 , CDKN2A and NID2 Genes in Urine Using a Nested Methylation Specific Polymerase Chain Reaction Assay to Predict Bladder Cancer

Scher, M. B., Elbaum, M. B., Mogilevkin, Y., Hilbert, D. W., Mydlo, J. H., Sidi, A. A., Adelson, M. E., Mordechai, E., & Trama, J. P. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.08.015 · Cited by 46 · see citing works

Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer

Goel, B., Tripathi, N., Bhardwaj, N., & Jain, S. K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200516152756 · Cited by 45 · see citing works

CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis

Aftab, A., Shahzad, S., Hussain, H. M. J., Khan, R., Irum, S., & Tabassum, S. (2018) · Breast Cancer · doi:10.1007/s12282-018-0894-0 · Cited by 43 · see citing works

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

Green, J. L., Okerberg, E. S., Sejd, J. R., Palafox, M., Monserrat, L., Alemayehu, S., Wu, J., Sykes, M., Aban, A., Serra, V., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0755 · Cited by 41 · see citing works

The Cyclin-dependent Kinase Inhibitor p16INK4a Physically Interacts with Transcription Factor Sp1 and Cyclin-dependent Kinase 4 to Transactivate MicroRNA-141 and MicroRNA-146b-5p Spontaneously and in Response to Ultraviolet Light-induced DNA Damage

Al‐Khalaf, H. H., Mohideen, P., Nallar, S. C., Kalvakolanu, D. V., & Aboussekhra, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512640 · Cited by 39 · see citing works

Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells

Seebauer, C. T., Brunner, S. M., Glockzin, G., Piso, P., Ruemmele, P., Schlitt, H. J., Geissler, E. K., Fichtner‐Feigl, S., & Kesselring, R. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1242543 · Cited by 38 · see citing works

Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma

Winter, H., Kaisaki, P. J., Harvey, J., Giacopuzzi, E., Ferla, M. P., Pentony, M. M., Knight, S. J. L., Sharma, R. A., Taylor, J. C., & McCullagh, J. (2019) · Cancers · doi:10.3390/cancers11121895 · Cited by 38 · see citing works

A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment

Cho‐Vega, J. H. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.70 · Cited by 37 · see citing works

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

Cocco, E., Deng, Y., Shapiro, E. M., Bortolomai, I., Lopez, S., Lin, K. Y., Bellone, S., Cui, J., Menderes, G., Black, J. D., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0501 · Cited by 37 · see citing works

Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?

Tsang, E. S., Topham, J. T., Karasinska, J. M., Lee, M. K. C., Williamson, L., Mendis, S. R., Denroche, R. E., Jang, G. H., Kalloger, S. E., Moore, R. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1042 · Cited by 36 · see citing works

Targeting CDK2 for cancer therapy

Knudsen, E. S., Witkiewicz, A. K., Sanidas, I., & Rubin, S. M. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116140 · Cited by 38 · see citing works

Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies

Janoštiak, R., Torres-Sanchez, A., Posas, F., & de Nadal, E. (2022) · Cancers · doi:10.3390/cancers14051265 · Cited by 36 · see citing works

Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct

Sasaki, M., Matsubara, T., Yoneda, N., Nomoto, K., Tsuneyama, K., Sato, Y., & Nakanuma, Y. (2012) · Histopathology · doi:10.1111/his.12016 · Cited by 35 · see citing works

Cuproptosis in lung cancer: mechanisms and therapeutic potential

Li, Q., Wang, T., Zhou, Y., & Shi, J. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04815-y · Cited by 34 · see citing works

p16INK4A Represses Breast Stromal Fibroblasts Migration/Invasion and Their VEGF-A-dependent Promotion of Angiogenesis through Akt Inhibition

Al‐Ansari, M. M., Hendrayani, S., Tulbah, A. M., Al‐Tweigeri, T., Shehata, A. I., & Aboussekhra, A. (2012) · Neoplasia · doi:10.1593/neo.121632 · Cited by 34 · see citing works

Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6

Gong, M., Luo, C., Meng, H., Li, S., Nie, S., Jiang, Y., Wan, Y., Li, H., & Cheng, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s227758 · Cited by 33 · see citing works

The protective effect of p16INK4a in oral cavity carcinomas: p16Ink4A dampens tumor invasion—integrated analysis of expression and kinomics pathways

Isayeva, T., Xu, J., Ragin, C. C. R., Dai, Q., Cooper, T. S., Carroll, W. R., Dayan, D., Vered, M., Wenig, B. M., Rosenthal, E. L., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.149 · Cited by 33 · see citing works

Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16 INK4a -Negative Cancer

Kwon, N. H., Lee, J. Y., Ryu, Y.-L., Kim, C., Kong, J., Oh, S., Kang, B. S., Ahn, H. W., Ahn, S. G., Jeong, J., et al. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00001 · Cited by 32 · see citing works

Expression of P16INK4a in Uveal Melanoma: New Perspectives

Russo, D., Crescenzo, R. M. D., Broggi, G., Merolla, F., Martino, F. D., Varricchio, S., Ilardi, G., Borzillo, A., Carandente, R., Pignatiello, S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.562074 · Cited by 32 · see citing works

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis

Shaya, J. A., Kato, S., Adashek, J. J., Patel, H., Fanta, P. T., Botta, G. P., Sicklick, J. K., & Kurzrock, R. (2023) · npj Genomic Medicine · doi:10.1038/s41525-022-00346-5 · Cited by 32 · see citing works

CtBP2 contributes to malignant development of human esophageal squamous cell carcinoma by regulation of p16INK4A

Guan, C., Shi, H. M., Wang, H., Zhang, J., Ni, W., Chen, B., Hou, S., Yang, X., Shen, A., & Ni, R. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24475 · Cited by 31 · see citing works

Cell Cycle Regulation in Treatment of Breast Cancer

Cai, Z., & Liu, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_12 · Cited by 30 · see citing works

Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia

Opitz, F. V., Häberle, L., Daum, A., & Esposito, I. (2021) · Cancers · doi:10.3390/cancers13246188 · Cited by 30 · see citing works

Tumor Milieu Controlled by RB Tumor Suppressor

Kitajima, S., Li, F., & Takahashi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072450 · Cited by 30 · see citing works

p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors

Romagosa, C., Simonetti, S., López-Vicente, L., Mazo, A., Lleonart, M. E., Castellvi, J., & Ramon y Cajal, S. (2011) · Oncogene · doi:10.1038/onc.2010.614 · Cited by 509 · see citing works

Tumor suppressor p16^(INK4a) in Cancer

이미현, 최부영, & Seo, Y. (2005) · 한국환경성돌연변이·발암원학회지 · Cited by 2 · see citing works

Mechanisms and Significance of the p16~(INK4a)/CDKN2A Gene Alterations in Human Tumors

Wang, G. (2000) · Zhejiang Cancer Journal

p16INK4a as a tumor suppressor with therapeutic applicability

Calbó, J., & Mazo, A. (2003) · Drugs of the Future · doi:10.1358/dof.2003.028.02.856928 · Cited by 2 · see citing works

The Tumor Suppressor Protein p16INK4a

Serrano, M. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3824 · Cited by 346 · see citing works